Tenax Therapeutics (TENX) CMO granted 250,000 stock options at $13.3
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Tenax Therapeutics, Inc. reported a new equity award to its chief medical officer and director, Stuart Rich. On January 9, 2026, he received a grant of stock options to buy 250,000 shares of common stock at an exercise price of $13.3 per share. These options vest over time, with 25% becoming exercisable on January 9, 2027 and the remaining shares vesting in equal monthly installments over the following 36 months, conditioned on his continued employment.
After this grant, he holds 5,266 shares of common stock directly, plus additional shares held indirectly through several family trusts. The filing states that he has voting or trustee roles with these trusts but disclaims beneficial ownership of their shares except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Rich Stuart
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 250,000 | $0.00 | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 250,000 shares (Direct);
Common Stock — 5,266 shares (Direct);
Common Stock — 1,194 shares (Indirect, By Stuart Rich 2022 Irrevocable Trust)
Footnotes (1)
- The Reporting Person is special asset advisor to the Stuart Rich 2022 Irrevocable Trust, a Spousal Lifetime Access Trust (the "Trust"). As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. The Reporting Person is co-trustee of the Andrea Rich 2021 Irrevocable Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The Reporting Person is trustee of the Stuart Rich Revocable Trust DTD 11/18/1996 and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment. The options vest and become exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA, subject to the Reporting Person's continued employment. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
FAQ
What did TENX disclose in this Form 4 filing?
The filing reports that chief medical officer and director Stuart Rich received a grant of stock options and lists his direct and indirect holdings of Tenax Therapeutics common stock.
How many Tenax Therapeutics (TENX) options were granted to Stuart Rich?
He was granted stock options for 250,000 shares of Tenax Therapeutics common stock on January 9, 2026.
What is the exercise price and vesting schedule of the new TENX stock options?
The options have an exercise price of $13.3 per share. 25% vest on January 9, 2027, and the remaining shares vest in equal monthly installments over the next 36 months, subject to his continued employment.
What indirect holdings of TENX stock are reported for Stuart Rich?
Indirect holdings include 1,194 shares held by the Stuart Rich 2022 Irrevocable Trust, 1,194 shares held by the Andrea Rich 2021 Irrevocable Trust, and 5,000 shares held by the Stuart Rich Revocable Trust DTD 11/18/1996.
Are there other TENX stock options held by Stuart Rich besides the new grant?
Yes. The filing lists additional stock options covering 157, 63, 119, 500,000, and 625,000 underlying shares, each with separate exercise prices and vesting schedules.